FY2025 EPS Estimates for Sanofi Decreased by Zacks Research

Sanofi (NASDAQ:SNY - Free Report) - Stock analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for shares of Sanofi in a research note issued on Tuesday, October 15th. Zacks Research analyst K. Shah now expects that the company will post earnings per share of $4.69 for the year, down from their previous forecast of $4.70. The consensus estimate for Sanofi's current full-year earnings is $4.26 per share. Zacks Research also issued estimates for Sanofi's Q1 2026 earnings at $1.33 EPS and FY2026 earnings at $5.08 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company's revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 EPS.

Other equities analysts also recently issued research reports about the company. StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Monday. Argus increased their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Finally, Citigroup raised shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Stock Up 0.8 %

Shares of NASDAQ:SNY traded up $0.42 during midday trading on Thursday, hitting $54.86. The stock had a trading volume of 1,051,037 shares, compared to its average volume of 2,023,744. The company has a market cap of $139.21 billion, a P/E ratio of 29.61, a PEG ratio of 1.57 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The business's 50-day simple moving average is $56.00 and its 200-day simple moving average is $51.46. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Boston Partners raised its stake in Sanofi by 0.3% during the first quarter. Boston Partners now owns 13,066,403 shares of the company's stock worth $635,280,000 after acquiring an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company's stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its position in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD grew its stake in shares of Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company's stock worth $192,023,000 after buying an additional 1,190,141 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company's stock worth $157,803,000 after buying an additional 246,224 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.